Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial. - Niemann CU; Dubois J; Nasserinejad K; da Cunha-Bang C; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; et al. (Blood advances, 2025)